Cargando…

Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D(2)/D(3) Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants

Trazpiroben (TAK‐906) is a peripherally selective dopamine D(2)/D(3) receptor antagonist being developed to treat chronic gastroparesis. This phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, parallel‐group study evaluated the safety, tolerability, pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Takayoshi, Kudou, Kentarou, Okamoto, Hiroyuki, Chen, Chunlin, Whiting, Roger, Sekino, Hisakuni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303893/ https://www.ncbi.nlm.nih.gov/pubmed/34967147 http://dx.doi.org/10.1002/cpdd.1057

Ejemplares similares

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D(2)/D(3) Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants
por: Whiting, Roger L., et al.
Publicado: (2021)

Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D(2)/D(3) Selective Receptor Antagonist for the Management of Gastroparesis
por: Kreckler, Laura, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D(2)/D(3) Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
por: Chen, Chunlin, et al.
Publicado: (2021)

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022)

Appropriate Needle Length Determined by Ultrasonic Echography for Intramuscular Injection in Japanese Elderly over 50 Years
por: Nakayama, Tetsuo, et al.
Publicado: (2022)

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
por: Sezai, Akira, et al.
Publicado: (2019)

The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study
por: Mukker, Jatinder K., et al.
Publicado: (2022)

Acquisition of Humoral Immune Responses in Convalescent Japanese People with SARS-CoV-2 (COVID-19) Infection in 2021
por: Monzen, Koshiro, et al.
Publicado: (2023)

Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects
por: Shiba, Sari, et al.
Publicado: (2020)

Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
por: Osuga, Yutaka, et al.
Publicado: (2021)

Effect of TAK‐085 on Low‐density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double‐blind Randomized Clinical Study
por: Tatsuno, Ichiro, et al.
Publicado: (2015)

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
por: Furihata, Kenichi, et al.
Publicado: (2021)

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
por: Fukushima, Yasushi, et al.
Publicado: (2018)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Disposition and Metabolism of Setipiprant, a Selective Oral CRTH2 Antagonist, in Humans
por: Hoch, Matthias, et al.
Publicado: (2013)

A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia
por: Sezai, Akira, et al.
Publicado: (2023)

A Comparative Study to Investigate the Effects of Bisoprolol in Patients with Chronic Heart Failure and Hypertension When Switched from Tablets to Transdermal Patches
por: Sezai, Akira, et al.
Publicado: (2023)

The ASCEND-ND trial: study design and participant characteristics
por: Perkovic, Vlado, et al.
Publicado: (2021)

Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants
por: Pefani, Eleni, et al.
Publicado: (2023)

Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
por: Hoshiai, Hiroshi, et al.
Publicado: (2021)

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)
por: Sezai, Akira, et al.
Publicado: (2019)

Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial
por: Singh, Ajay K, et al.
Publicado: (2021)

Epigenetic and genetic dispositions of ovarian carcinomas
por: Yamaguchi, Ken, et al.
Publicado: (2014)

Efficacy of Early Cardiac Rehabilitation After Cardiac Surgery　― Verification Using Japanese Diagnosis Procedure Combination Data ―
por: Sezai, Akira, et al.
Publicado: (2022)

Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer
por: Hill, Christopher R., et al.
Publicado: (2014)

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide
por: Bins, S, et al.
Publicado: (2017)

Nuclear Disposition of Alien Chromosome Introgressions into Wheat and Rye Using 3D-FISH
por: Koláčková, Veronika, et al.
Publicado: (2019)

Dispositions : a debate /
por: Armstrong, D. M. (David Malet), 1926-
Publicado: (1996)

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
por: Yoshida, Tatsuya, et al.
Publicado: (2023)

Single exposure of dopamine D1 antagonist prevents and D2 antagonist attenuates methylphenidate effect
por: Claussen, Catherine M, et al.
Publicado: (2015)

Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
por: Suzuki, Kazuhiro, et al.
Publicado: (2015)

Transcatheter Treatment of Ascending Aorta Pseudoaneurysm Guided by 3D-Model Technology
por: Santoro, Giuseppe, et al.
Publicado: (2022)

Disposition générale
Publicado: (1966)

Representing dispositions
por: Röhl, Johannes, et al.
Publicado: (2011)

Commentary on: “Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide”
por: Morrissey, KM, et al.
Publicado: (2017)

Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
por: Tanuma, Yasushi, et al.
Publicado: (2016)

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil
por: Tanuma, Yasushi, et al.
Publicado: (2021)

A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants
por: Dube, Louise, et al.
Publicado: (2023)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p8b964f7pdhbsp454ebnhsb4gl